<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533364</url>
  </required_header>
  <id_info>
    <org_study_id>SBG-2-01</org_study_id>
    <nct_id>NCT00533364</nct_id>
  </id_info>
  <brief_title>Effect of SBG in Patients With Breast Cancer</brief_title>
  <official_title>A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotec Pharmacon ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotec Pharmacon ASA</source>
  <brief_summary>
    <textblock>
      This study is set up to determine whether soluble beta-glucan (SBG) has

        -  unfavourable side effects

        -  beneficial treatment effects when given in combination with standard antibody and
           chemotherapy to patients with breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asess the safety of SBG in combination with standard antibody and chemotherapy treatment</measure>
    <time_frame>21 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBG (Soluble beta-glucan)</intervention_name>
    <description>Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with histologically/cytologically confirmed locally advanced or metastatic
             breast cancer

          2. Primary tumor or metastases are HER2-ICH3+ or FISH+

          3. Measurable or non-measurable disease

          4. The patients must not have received treatment with the combination trastuzumab and
             vinorelbine previously

          5. Expected lifetime of more than 12 weeks

          6. Age ≥ 18 years

          7. Performance status ≤ 2 according to World Health Organization (WHO) scale

          8. The patient must be able to comply with the protocol

          9. Verbal and written informed consent

        Exclusion Criteria:

          1. Women who are pregnant or breast-feeding. A negative pregnancy test must be provided
             during the screening period for fertile women. Fertile women must use effective
             contraceptive methods

          2. Clinical symptoms indicating central nervous system involvement

          3. Other current or former malignant disease, with the exception of adequately treated
             and cured carcinoma in situ cervicis uteri and basocellular skin carcinomas

          4. Left ventricular ejection fraction (LVEF) &lt; 50% of normal range

          5. Reduced bone marrow function defined by leukocyte counts &lt; 3.0 x 109/l and neutrophil
             counts &lt; 1.5 x 109/l, or thrombocyte counts ≤ 100 x 109/l

          6. Reduced liver function defined by bilirubin &gt; 3 x upper normal limit and/or ASAT/ALAT
             &gt; 3 x upper normal limit and/or alkaline phosphatase &gt; 3 x upper normal limit.

          7. Reduced renal function defined by serum creatinine &gt; 2 x upper normal limit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Wist, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>February 17, 2010</last_update_submitted>
  <last_update_submitted_qc>February 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>VP Clinical Development</name_title>
    <organization>Biotec Pharmacon ASA</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

